Immunic Inc. [NASDAQ: IMUX] closed the trading session at $22.00 on 08/03/20. The day’s price range saw the stock hit a low of $20.20, while the highest price level was $23.39. The company report on August 3, 2020 that Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock.
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it intends to offer and sell 5 million shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters an option for 30 days to purchase up to an additional 750,000 shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
SVB Leerink and Piper Sandler are acting as joint bookrunning managers for the proposed offering. Wedbush PacGrow and Ladenburg Thalmann are acting as co-managers for the proposed offering.
The stocks have a year to date performance of 126.80 percent and weekly performance of 32.13 percent. The stock has been moved at 145.54 percent over the last six months. The stock has performed 78.86 percent around the most recent 30 days and changed 169.61 percent over the most recent 3-months.
If compared to the average trading volume of 363.49K shares, IMUX reached to a volume of 3677946 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Immunic Inc. [IMUX]:
BMO Capital Markets have made an estimate for Immunic Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 20, 2020. While these analysts kept the previous recommendation, Wedbush raised their target price to Outperform. The new note on the price target was released on June 05, 2020, representing the official price target for Immunic Inc. stock. Previously, the target price had yet another raise to $45, while H.C. Wainwright analysts kept a Buy rating on IMUX stock.
The Average True Range (ATR) for Immunic Inc. is set at 1.63 The Price to Book ratio for the last quarter was 4.68, with the Price to Cash per share for the same quarter was set at 1.22.
IMUX stock trade performance evaluation
Immunic Inc. [IMUX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.13. With this latest performance, IMUX shares gained by 78.86% in over the last four-week period, additionally plugging by 145.54% over the last 6 months – not to mention a rise of 63.69% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IMUX stock in for the last two-week period is set at 77.33, with the RSI for the last a single of trading hit 83.09, and the three-weeks RSI is set at 73.46 for Immunic Inc. [IMUX]. The present Moving Average for the last 50 days of trading for this stock 13.53, while it was recorded at 17.81 for the last single week of trading, and 9.48 for the last 200 days.
Immunic Inc. [IMUX]: An insightful look at the core fundamentals
Return on Total Capital for IMUX is now -103.86, given the latest momentum, and Return on Invested Capital for the company is -97.98. Return on Equity for this stock declined to -98.69, with Return on Assets sitting at -86.33. When it comes to the capital structure of this company, Immunic Inc. [IMUX] has a Total Debt to Total Equity ratio set at 0.89. Additionally, IMUX Total Debt to Total Capital is recorded at 0.88, with Total Debt to Total Assets ending up at 0.79. Long-Term Debt to Equity for the company is recorded at 0.89, with the Long-Term Debt to Total Capital now at 0.88.
Reflecting on the efficiency of the workforce at the company, Immunic Inc. [IMUX] managed to generate an average of -$1,343,577 per employee.Immunic Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.70 and a Current Ratio set at 3.70.
Earnings per share (EPS) analysis for Immunic Inc. [IMUX] stock
With the latest financial reports released by the company, Immunic Inc. posted -0.82/share EPS, while the average EPS was predicted by analysts to be reported at -0.67/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -22.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IMUX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Immunic Inc. go to 15.50%.
Immunic Inc. [IMUX]: Insider Ownership positions
There are presently around $50 million, or 20.90% of IMUX stock, in the hands of institutional investors. The top three institutional holders of IMUX stocks are: OMEGA FUND MANAGEMENT, LLC with ownership of 1,371,494, which is approximately 0% of the company’s market cap and around 2.30% of the total institutional ownership; ARTAL GROUP S.A., holding 630,019 shares of the stock with an approximate value of $13.86 million in IMUX stocks shares; and INTERNATIONAL BIOTECHNOLOGY TRUST PLC, currently with $2.71 million in IMUX stock with ownership of nearly New of the company’s market capitalization.
Positions in Immunic Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 12 institutional holders increased their position in Immunic Inc. [NASDAQ:IMUX] by around 153,418 shares. Additionally, 5 investors decreased positions by around 5,336 shares, while 13 investors held positions by with 2,131,578 shares. The mentioned changes placed institutional holdings at 2,290,332 shares, according to the latest SEC report filing. IMUX stock had 6 new institutional investments in for a total of 137,803 shares, while 2 institutional investors sold positions of 408 shares during the same period.